Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Immunotherapy Rationale in Multiple Myeloma

July 27th 2016

Where Immuno-Oncology Is Heading

July 20th 2016

Brentuximab Vedotin in Advanced Lymphoid Malignancies

July 20th 2016

Anti-CD20 Antibodies for Advanced Hematologic Malignancies

July 20th 2016

Obinutuzumab for Indolent Lymphoma

July 20th 2016

Immunochemotherapy for Lymphoma

July 20th 2016

Resistance with CAR-T Therapy

July 20th 2016

Where Does CAR-T Fit in the Context of Transplant?

July 20th 2016

Recent Trials of CAR-T Therapy

July 20th 2016

Toxicity Management for CAR-T in Hematologic Malignancies

July 20th 2016

Obstacles to Using CAR-T Therapy in Hematologic Malignancies

July 20th 2016

CAR-T Cell Therapy in Hematologic Malignancies

July 20th 2016

The Potential for Combining Checkpoint Inhibitors

July 20th 2016

Immunotherapy for Follicular Lymphoma

July 20th 2016

Immunotherapy in Refractory DLBCL

July 20th 2016

PD-1 Inhibitors in Hodgkin Lymphoma

July 20th 2016

Immunotherapy Response Among Hematologic Malignancies

July 20th 2016

Immunotherapy: What is the Role in Lymphoid Cancers?

July 20th 2016

Obinutuzumab Falls Short in Phase III DLBCL Trial

July 18th 2016

Adding the anti-CD20 agent obinutuzumab (Gazyva) to CHOP chemotherapy in the frontline setting did not improve progression-free survival compared with the standard regimen of rituximab (Rituxan) plus CHOP in patients with diffuse large B-cell lymphoma.

Preliminary Data for Duvelisib in Indolent NHL

June 29th 2016